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Introduction: Hsp60 (Cpn60) assembles into a tetradecamer that interacts with
the co-chaperonin Hsp10 (Cpn10) to assist client polypeptides to fold, but it
also has other roles, including participation in pathogenic mechanisms.
Area covered: Hsp60 chaperonopathies are pathological conditions, inherited
or acquired, in which the chaperone plays a determinant etiologic-pathogenic
role. These diseases justify selection of Hsp60 as a target for developing agents
that interfere with its pathogenic effects. We provide information on how
to proceed.
Expert opinion: The information available encourages the development of
ways to improve Hsp60 activity (positive chaperonotherapy) when deficient
or to block it (negative chaperonotherapy) when pathogenic. Many questions
are still unanswered and obstacles are obvious. More information is needed
to establish when and why autologous Hsp60 becomes a pathogenic autoan-
tigen, or induces cytokine formation and inflammation, or favors carcinogen-
esis. Clarification of these points will take considerable time. However,
analysis of the Hsp60 molecule and a search for active compounds aimed at
structural sites that will affect its functioning should continue without inter-
ruption. No doubt that some of these compounds will offer therapeutic hopes
and will also be instrumental for dissecting structure--function relationships at
the biochemical and biological (using animal models and cultured cells) levels.
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1. The chaperonopathies and their treatment
Chaperonopathies are diseases in which molecular chaperones play an etiolo-
gic--pathogenic role [1]. The pathogenic chaperone may be normal (or apparently
normal, considering our current means of molecular analysis) or structurally altered
(mutation or aberrant post-translation modification) and belong to any of the
known Hsp-chaperones groups, Table 1. The structural alteration of a pathological
chaperone may affect any of its functional domains or modules, Figure 1. The
impact on function will be strongest on, or will exclusively affect, the particular
function of the module in which the structural alteration is located.
From the clinicopathological standpoint, quantitative chaperonopathies are char-
acterized by an increase or decrease of the pathological chaperone in the affected cell
and tissue [2]. If the increased or decreased chaperone is the etiologic--pathogenic
factor, the disease is a primary chaperonopathy. However, in various pathological
conditions, one or more chaperones are increased or decreased, but they are not
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etiologic--pathogenic factors; these are secondary chaperono-
pathies, in which the quantitative alterations of the chaper-
ones are the consequence and not the cause of the disease.
In secondary chaperonopathies, the levels of the chaperones
affected may serve as indicators (biomarkers) of disease status
and response to treatment.
The molecular chaperones and their co-chaperones and co-
factors of any given organism constitute the chaperoning sys-
tem [2]. The components of the chaperoning system form
functional teams (chaperoning machines) and networks,
involved not only in protein homeostasis (the canonical func-
tion of chaperones) but also in various other cellular processes
that are not related to protein quality control. Therefore, fail-
ure of a single chaperone type may have far-ranging conse-
quences, affecting diverse physiological mechanisms in
various tissues, since components of the chaperoning system
are present throughout the organism, inside and outside cells,
and in circulation.
Chaperonopathies have been classified considering their
biologic and molecular mechanisms into by defect, by excess
or by mistake, Table 2 [3]. This classification is useful to estab-
lish a diagnosis with physiopathological implications and,
thus, aids in decisions on treatment. Further, the classification
is instrumental to conduct a differential diagnosis exercise that
will lead to an accurate identification of syndrome and dis-
ease, which is key to proper patient management.
Another way of classifying chaperonopathies that will also
help the physician and, therefore, the patient, is based on
whether they are inherited (genetic) or acquired. Table 3 dis-
plays information about the human Hsp60 gene and protein
and gives examples of its genetic chaperonopathies [2].
While Figure 2 outlines the molecular anatomy of Hsp60 (see
further), Figure 3 shows the location of the two amino acids
in Hsp60 whose mutation cause disease as described
in Table 3. The mutations V98I, causing spastic paraplegia
SPG13, and D29G, causing MitCHAP-60 disease, were
Article highlights.
. Chaperonopathies. Chaperonopathies are diseases recently organized in a coherent nosological group in which the
determinant etiologic--pathogenic factor is a molecular chaperone. In some chaperonopathies, factors other than the
pathogenic chaperone may also be involved. The pathogenic chaperone may appear normal at the molecular level (at least
considering today’s methods of detection of protein abnormalities) or be abnormal. In the latter case, the pathogenic
chaperone has structural alterations due to mutation or aberrant-post-translational modification.
. Types of chaperonopathies. Chaperonopathies can be classified into genetic (hereditary) and acquired or, considering
mechanism and levels of concentration and activity, into by defect, excess or mistake.
. Hsp60 chaperonopathies. A chaperone that can cause disease is Hsp60. In humans, its canonical residence is the
mitochondrion, but it can also reside and work outside this organelle, in the cytosol, cell membranes, extracellular space,
biological fluids (plasma, cerebrospinal fluid) and secretions (saliva, urine). The canonical function of Hsp60 in the human
mitochondrion (also named Cpn60) consists of assisting newly synthesized polypeptides in folding correctly. However,
Hsp60 plays many other roles beyond the mitochondria that are unrelated to protein folding.
. Hsp60 functional oligomers and interaction with Hsp10. To exercise its typical chaperoning role, Hsp60 assembles into
an oligomer with a well-defined quaternary structure which, in turn, interacts with an oligomer of the co-chaperonin
Hsp10 (Cpn10). The whole process depends on specific sites on the Hsp60 and Hsp10 molecules, most of which have been
mapped, and requires ATP hydrolysis.
. Hsp60 functional structural modules. The Hsp60 molecule is composed of various functional modules with distinct roles. If
any of these modules is altered by a mutation, post-translational modification, or by the binding of a specific chemical
compound, its functions may be seriously disrupted. This might lead to failure of the entire molecule with ensuing disease.
. Genetic Hsp60 chaperonopathies. Hereditary spastic paraplegia SPG13, and MitCHAP-60 disease are genetic
Hsp60 chaperonopathies by defect, in principle amenable to chaperonotherapy by gene or protein replacement.
. Acquired Hsp60 chaperonopathies. Examples of Hsp60 acquired chaperonopathies include diverse conditions characterized
by chronic inflammation and autoimmunity, and various types of cancer. In these pathologies, Hsp60 plays a pathogenic role
as autoantigen, or as inducer of inflammatory cytokines, or as facilitator of cancer development and growth.
. Hsp60 as therapeutic target. As seen earlier, there are many Hsp60 chaperonopathies and candidates to be classified as
such, pending more studies. Because of the variety of disorders in which Hsp60 is likely to play a determinant role, and
because of its wide range of roles and distribution throughout the organism, the development of therapeutic means to either
replace or improve the activity of a defective Hsp60 (positive chaperonotherapy) or to eliminate or block it when pathogenic
(negative chaperonotherapy) are amply justified. However, because Hsp60 is present in all cells and cell compartments, it will
be of the essence to develop very specific compounds and delivery systems targeting only the pathogenic molecule in the
abnormal cell, for instance tumor cell.
. From the present to the future. This article provides information and suggestions on how and why to proceed with the
analysis of human Hsp60 in its various forms and locations to understand its molecular features, normal and abnormal, and
the mechanisms by which it causes pathology, and to verify its real value as biomarker of disease. These investigations should
provide, for instance, information on how to monitor and control (block or eliminate) this chaperonin when it becomes a
pathogenic factor, or to replace it or boost its activity when defective.
This box summarizes key points contained in the article.
F. Cappello et al.
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Table 1. Subpopulations of Hsp-chaperones classified according to apparent molecular weight.
MW (kDa) range Classical family Examples of other Hsp-chaperones implicated in the causation
of chaperonopathies
200 or higher None Sacsin
100 -- 199 Hsp100-110
81 -- 99 Hsp90 Paraplegin [SPG7]
65 -- 80 Hsp70/DnaK Spastin [SPG4]; LARP7
55 -- 64 Hsp60 (chaperonins Groups I and II,
e.g., Cpn60 and CCT, respectively)
Myocilin; protein disulphide-isomerases or PDIs
35 -- 54 Hsp40/DnaJ AIP; AIPL1; torsin A; clusterin; DNAJC19 (TIM14)
34 or less sHsp (crystallins) Hsp10 (Cpn10); Alpha hemoglobin-stabilizing protein or AHSP;
cyclophilin type peptidyl-prolyl cis-trans isomerases or PPIs;
alpha-synuclein; HSPB11
Adapted from [2,105].
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ATP
ATP
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Substrate binding
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oligomerization >
chaperone complex
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binding >
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interaction > no
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No subunit
binding >
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ATP
ATP
ADP
Figure 1. Schematic representation of the structural--functional domains or modules of a typical molecular chaperone. The
key, starting with the circle, from left to right in the top-left scheme is ATP-binding-ATPase, substrate binding, chaperone or
cofactor--chaperone interaction (needed for the assembly of the chaperoning networks, that is, interaction with other
chaperones and chaperoning teams), oligomerization (needed for the formation of oligomers, that is, the chaperoning
complex or team such as the homoheptamer formed by Hsp60 or the hetero-octamer characteristic of CCT); hinge (needed for
allowing the allosteric changes accompanying all functions of the chaperone molecule -- several of these domains are usually
present); ubiquitin--proteasome interaction (needed for interaction with the ubiquitin--proteasome system for protein
degradation). Filled forms represent structurally altered domains due to mutation or post-translational modification, or to
the binding of a chemical compound. Note: Not all chaperones have all these functional modules, and they are not necessarily
distributed along the molecule as shown in this schematic drawing.
UPS: Ubiquitin-proteasome system.
Adapted from [2].
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described several years ago [4-6]. D29 is at a position located in
the equatorial domain interface and does not seem to be
involved directly in the interactions between Hsp60 mono-
mers. However, aspartic acid (D) is medium sized, acidic, acy-
clic, negative and polar, whereas glycine (G), which replaces it
in the mutant, is acyclic, aliphatic, hydrophobic, small sized
and neutral. It is expected that these differences between the
wild type and the mutant residues will affect charge distribu-
tion and equatorial domain interaction, resulting in
impairment of the Hsp60 functions. Valine (V) is acyclic, ali-
phatic, hydrophobic, medium sized and neutral, whereas iso-
leucine (I), which replaces it in the mutant, is acyclic,
aliphatic, hydrophobic, large and neutral. The 98th position
is critical because it is very close to the end of the sequence
85-AGDGTTTATVL-95 implicated in ATP and Mg+ bind-
ing [7]. It is, therefore, probable that isoleucine instead of valine
at that position will have a strong impact (e.g., steric hindrance
due to its large size) on nucleotide and ion binding, which will
inactivate the chaperonin. See also Figure 1A and B.
Acquired chaperonopathies affecting Hsp60 are discussed
later. Chaperonotherapy includes any therapeutic means tar-
geted to a chaperone with the purpose of correcting a chaper-
onopathy [8]. When the chaperone is deficient, the aim is to
replace it or to boost its functionality, and we can refer to
this therapeutic modality as positive chaperonotherapy. If,
on the contrary, the chaperone favors disease rather than pro-
tection of the cell and the organism, the therapeutic strategy
aims at eliminating or blocking the pathological chaperone.
This latter therapeutic modality may be referred to as negative
chaperonotherapy. These basic premises are important in
practice because they offer the clinicians and pathologists a
stand point that provides a good perspective of the field and
its subfields and, thus, enables them to envisage what is best
to control the disease at hand and treat the patient more effec-
tively. Further, these basic ideas allow a better organization of
data than would be possible without a scaffold on to which
new information can be added and, consequently, these ideas
will show possible routes for investigation and for developing
novel treatments. The concept that a chaperone may be a
determinant etiologic--pathogenic factor in some diseases
should open a new window to look at patients and discover
pathogenic mechanisms until now either misinterpreted or
simply ignored. No doubt that medical and pharmacological
research will benefit from this novel outlook. In this article,
we present a brief account on Hsp60 chaperonopathies and
on the possible ways that might be followed for developing
Table 2. Classification of chaperonopathies according to pathogenic mechanism.
Chaperonopathies by Mechanism, features
Excess Quantitative, e.g., due to gene dysregulation and overexpression
Qualitative, e.g., gain of function
Defect Quantitative, e.g., gene downregulation
Qualitative, e.g., due to structural defect genetic or acquired
Mistake Normal chaperones can contribute to disease, e.g., some tumors that need chaperones to grow;
autoimmune conditions in which a chaperone is the autoantigen; and possibly also prion
diseases in which chaperones may be required for propagation.
Adapted from [2,3].
Table 3. Human Hsp60 gene and protein, and mutations.
Gene Name Cytogenetic location Structure Protein
HSPD1 HGNC:5261 Hsp60; HSP60; HSPD1; heat-shock
60-Kd protein 1; chaperonin, 60-Kd;
CPN60; Cpn60; GroEL, E. coli,
homolog of
2q33.1 12 exons
(first non-coding)
Variants: 2
UniProtKB/Swiss-Prot P10809
573 aa Isoforms: 2
Mutation Disease (mutation phenotype)
name (and synonyms)
Phenotype MIM
number
Gene locus
MIM number
Val98Ile (V98I)
Gln461Glu (Q461E)
Spastic Paraplegia 13, autosomal
dominant; SPG13
605280 118190
Asp29Gly (D29G) Leukodystrophy, hypomyelinating, 4;
HLD4; mitochondrial
HSP60 chaperonopathy;
MitCHAP-60 disease
612233 118190
Adapted from [2,106,107], and the following Databases: Hugo Gene Nomenclature Committee (HGNC; http://www.genenames.org/); Online Mendelian Inheritance
in Man (OMIN; http://omim.org/); UniProt (http://www.uniprot.org/); National Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/guide/);
and PubMed-NCBI (http://www.ncbi.nlm.nih.gov/pubmed).
F. Cappello et al.
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treatments targeting the chaperonin. For instance, the diseases
referred to in Table 3 are caused by severe impairment of
Hsp60 functions and should be considered candidates for
positive chaperonotherapy, using the normal Hsp60 gene or
protein to replace the defective molecule in the patients.
2. The concept of chaperonopathy by
mistake: the case of Hsp60
Chaperonopathies by mistake occur when a normal (or appar-
ently normal since some changes, for instance some post-
translational modifications, may be difficult to detect with
technology available today) chaperone functions to favor a
pathogenic mechanism leading to a disease. Examples are
some forms of autoimmune and chronic inflammatory dis-
eases as well as some forms of cancer. In the following para-
graphs, we report information concerning diseases in which
Hsp60 act as a) autoantigen, participating in the mechanism
of autoimmunity; b) chaperokine, inducing cytokine produc-
tion and leading to chronic inflammation; and c) factor pro-
moting cancer initiation and/or growth, and/or local spread,
and/or distant spread (metastasis), and/or resistance to treat-
ment, or any other procancer mechanism [2].
The participation of Hsp60 in many of these diseases has
been inferred from observations of very close correlations
between abnormalities in the chaperonin and disease onset,
progression, response to treatment and patient status with
time and between the histological location of the chaperonin
with levels of inflammatory cells and levels of cytokines in
the pathological tissue. The chaperonin abnormalities are
not only quantitative, that is, increase or decrease, but also
in distribution, for example, the chaperonin may appear or
increase above normal levels in places other than the canonical
location inside the mitochondria, such as the cytosol, vesicles,
the plasma membrane and blood; or it may appear at detect-
able levels in cells in which it is normally undetectable. All
these observations strongly implicate Hsp60 in pathogenesis;
but in most instances, a direct demonstration of cause effect
is still incomplete, and research must continue to elucidate
this critical issue. Nevertheless, it is safe to say that the future
is promising, as indicated by a series of reports, some of which
have been highlighted in the Bibliography.
3. Hsp60 and autoimmune diseases
Both, microbial and human Hsp60 have been proposed to
have a role in the pathogenesis of autoimmune diseases. The
mechanism by which Hsp60 may act as autoantigen is based
on molecular mimicry due to the high sequence similarity
between human and foreign Hsp60 from bacteria and
parasites that colonize humans, which leads to anti-Hsp60
antibody cross-reactivity [2] For example, mycobacterial
Hsp65 (mHsp65), the active factor in complete Freund’s
adjuvant used to induce autoimmune disease in experimental
animals, stimulates innate immunity via TLR pathways [9].
Another example pertains to the Hsp60 from Chlamydia tra-
chomatis serovar D, which was compared with the human
counterpart [10]. The amino-acid sequences were aligned and
a high percentage of identity was found in 17 regions that
could be presented to T cells by the MHC class I molecules,
triggering an autoimmune response. This led us to postulate
a crucial role of molecular mimicry between Chlamydial and
human Hsp60 in the pathogenesis of some autoimmune
diseases [11]. Table 4 shows a list of diseases in which molecular
mimicry between microbial and human Hsp60 may be
involved in generation of autoimmunity.
The high structural similarity between Hsp60 and other
human proteins (e.g., myelin-associated protein, glutamic
Intermediate
domain
Apical
domain
Equatorial 
domain
Figure 2. The anatomy of the human Hsp60: structural
domains. The cartoon represents a three-dimensional model
of the human Hsp60 monomer showing its three structural
domains: apical in green, intermediate in yellow and
equatorial in red. These structural domains are not the
same as the functional domains or modules schematized
in Figure 1 but contain them. The material and methods for
cons t ruct ing the images in th i s F igu re 2 and
subsequent Figures 3,4,5,6,7, were as follows: The amino-
acid sequence of the human Hsp60 was retrieved from the
PubMed website (http://www.ncbi.nlm.nih.gov/genbank/),
using the accession number NM_002156. The three-
dimensional model of the Hsp60 monomer was build using
a fully automated protein structure homology-modeling
server named SWISS-MODEL (http://swissmodel.expasy.org/)
[203-205] accessible via the ExPASy web server (http://www.
expasy.org/). The three-dimensional model of the tetrade-
cameric GroEL alone and of the Gro-EL/GroES complex
(Figures 8,9,10,11) were obtained from http://www.rcsb.org/
pdb/home/home.do with PDB codes 4AAR and 1PQC,
respectively [206,207]. All models were visualized and mod-
ified by PyMol (http://www.pymol.org).
Hsp60 chaperonopathies and chaperonotherapy: targets and agents
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acid decarboxylase and acetylcholine receptor) suggested that
Hsp60, when released into the circulation, may serve as auto-
antigen for generating an autoimmune response [12]. In turn,
it may trigger autoimmune pathological conditions, too, like
multiple sclerosis, type 1 diabetes, atherosclerosis and Myas-
thenia gravis. Tables 5 and 6 contain lists of diseases in which
cross-reactivity between human Hsp60 and other human
molecules may be involved in generating autoimmunity.
4. Hsp60 and chronic inflammatory diseases
Hsp60 has been shown to activate inflammatory cells that are
induced to produce cytokines and other mediators of inflam-
mation. Hence, Hsp60 is able to function as “chaperokine”
[13]”. For example, it can activate human monocyte/
macrophage cells by binding to CD14 with subsequent activa-
tion of p38MAPK, in turn stimulating these cells to synthe-
size proinflammatory cytokines (such as TNFa, IL-12 and
IL-15) and nitric oxide [14,15]. Hsp60 can bind to TLR2 and
TLR4 expressed on T cells and, thereby, contribute to either
induction or termination of immune responses by controlling
the activities of innate and adaptive immune cells [16].
Moreover, Hsp60 can bind to the neutrophils’ plasma mem-
brane, enhancing production of oxidants and release of
proteases [17].
Expression of Hsp60 can be triggered by various stressors
typical of chronic inflammatory diseases, as shown for exam-
ple for atherosclerosis [18]. Importantly, the expression of
Hsp60 in stressed vascular endothelial cells is always accompa-
nied by the simultaneous expression of adhesion molecules.
This situation then allows for attachment of Hsp60-reactive
T-cells to target endothelial cells.
We found elevated levels of Hsp60 in the macrophages of
the lamina propria in the large-bowel mucosa of patients
with ulcerative colitis (UC) [19]. The number of Hsp60-posi-
tive macrophages diminished after therapy in parallel with a
reduction of mucosal inflammation and with amelioration
of the patients’ symptoms, thus providing evidence that
Hsp60 is associated with inflammation in UC. Moreover,
we found Hsp60 in the neutrophils of the lamina propria in
the airways mucosa of patients with chronic obstructive pul-
monary disease (COPD) [20]. We also found a correlation
between the number of Hsp60-positive cells and the number
of neutrophils in patients with COPD, suggesting that this
chaperonin plays a role in controlling neutrophil functions
and, in turn, bronchial inflammation. Table 6 shows a list of
chronic inflammatory conditions in which Hsp60 has been
implicated as a stimulator of inflammation. Some of the
pathologies listed in Table 6 are autoimmune conditions.
This is due to the fact that autoimmune and inflammatory
chronic diseases can overlap.
5. Hsp60 and cancer
Hsp60 levels change during the carcinogenetic steps in various
organs, such as oral cavity [21], uterine cervix [22], large
bowel [23], prostate [24] and the bronchial tree [25,26]. This
implies that this chaperonin is involved, directly or indirectly,
in carcinogenesis of these organs. Table 7 lists examples of
tumors in which Hsp60 levels have been found changed, in
comparison with the normal tissue counterparts. Also, cellular
distribution of Hsp60 changes during carcinogenesis: the
chaperonin accumulates in extramitochondrial sites, such as
cytosol, plasma membrane and secretory vesicles [27,28]. Data
from various laboratories indicate that extramitochondrial
Hsp60 may have some direct role in tumor transformation
of normal tissues as well as in tumor progression. For
instance, (i) cytosolic Hsp60 is involved in caspase-3 cleavage
and apoptosis activation in non-tumor [29,30] and in
tumor [31,32] cells; and (ii) cytosolic Hsp60 is secreted by
tumor cells by both, the classic (Golgi’s) and alternative (exo-
somal) pathways [28]. It remains to be established how the
Hsp60 molecule reaches the cytosol, plasma membrane and
secretory vesicles. Questions still unanswered are the follow-
ing: Does Hsp60 migrate out of the mitochondria into the
cytosol, or does it remain in the cytosol after being synthe-
sized, or both?
V98
V98
D29
D29
G29
G29
I98
I98
Figure 3. Mutations that cripple Hsp60 and cause disease in
humans. The top panels represent the whole
Hsp60 molecule, whereas the bottom panels show enlarged
the portion of the molecule in which the mutations occur.
Left panels: wild type Hsp60, with the amino acids
V98 (yellow) and D29 (red) highlighted. Right panels: the
mutants V98I, causing spastic paraplegia SPG13 (yellow), and
D29G, causing MitCHAP-60 disease (red), are highlighted.
These mutations appear to alter the molecular anatomy of
Hsp60 to the point of making it functionally defective (see
text, Table 3, and Figure 1A and B).
F. Cappello et al.
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The quantity of Hsp60 contained in tumor-derived exo-
somes depends on the action of some stressors [33,34], and
the Hsp60-carrying exosomes appear to be involved in modu-
lating antitumor immune response [33].
Hsp60 has been found to accumulate in lymph node-
invading tumor cells as well as in neoangiogenic islets in pri-
mary tumors [35], both findings suggesting involvement of
Hsp60 in lymph node and distant organ metastasis.
Azacytidine, a chemotherapeutic agent, has been found to
induce an increase of Hsp60 levels in tumor cells, and this
increase has been related to an increased tumor resistance to
therapy [36].
These data and many others from diverse laboratories let us
to postulate that some forms of tumor may now be considered
chaperonopathies by mistake (or by collaborationism, since
the chaperone collaborates with the tumor, i.e., the “enemy”).
In these cases, Hsp60 participates actively in tumor formation
and progression by protecting tumor cells from external envi-
ronment stressors and by favoring their proliferation. As a
consequence, the inhibition of the protumoral Hsp60 effects
(negative chaperonotherapy) may be a new therapeutic approach
for treatment of some tumors.
6. Hsp60 can interact directly with molecules
in various cell compartments
Hsp60 is classically described as a mitochondrial protein
localized to the mitochondrial matrix, constitutively expressed
Table 4. Examples of diseases in which molecular mimicry between microbial and human Hsp60 may be involved
in generation of autoimmunity.
Organ/system Disease Pathogen Ref.
Central nervous system Multiple sclerosis Unknown [108]
Heart Ischemic disease Chlamydia pneumoniae [109]
Lung Asthma Chlamydia pneumoniae [110]
Muscle (neuromuscular junction) Myasthenia gravis Chlamydia trachomatis [111,112]
Vessels Atherosclerosis Escherichia coli and Chlamydia pneumoniae [113]
Helicobacter pylori [114,115]
Porphyromonas gingivalis [116]
Adapted from [2].
Table 5. Examples of diseases in which cross-reactivity between human Hsp60 and other human molecules may be
involved in generating autoimmunity.
Organ/system Disease Human molecule with high similarity to Hsp60 Ref.
Adrenal gland Addison’s disease 17 alpha Hydroxylase [117]
21 Hydroxylase [118]
Central nervous system Multiple sclerosis Myelin-associated protein [119]
Neurofilament triplet M protein [120]
Cerebellum Paraneoplastic cerebellar degeneration Cerebellar degeneration associated protein [121]
Heart Coxsackie myocarditis Cardiac myosin heavy chain [122]
Kidney Basement membrane disease Laminin beta 2 chain [123]
Glomerulonephritis Myeloperoxidase [124]
Liver Chronic active hepatitis Cytochrome P450 [125]
Primary biliary cirrhosis Pyruvate dehydrogenase [126]
NADH dehydroreductase [127]
Dihydrolipoamide dehydrogenase [128]
Lung and kidney Goodpasture’s syndrome Laminin beta 2 chain [123]
Neuromuscular junction Myasthenia gravis Acetylcholine receptor [129]
Pancreas Diabetes insulin dependent Glutamic acid decarboxylase [130]
Skin Pemphigoid Bullous pemphigoid antigen [131]
Scleroderma KU autoimmune antigen [132]
Synovial joints Rheumatoid arthritis Cytokeratin [118,133]
Thyroid Hashimoto’s thyroiditis Thyroglobulin [134]
Various Systems Systemic lupus erythematosus DNA-binding protein [135]
Hsp90 [136]
Adapted from [2].
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under normal conditions, and induced by heat shock, mito-
chondrial damage, mtDNA depletion and other kinds of
stressors [37]. However, a number of studies demonstrated
that Hsp60 can also localize to extramitochondrial sites such
as the cytosol and the plasma membrane, and circulate in
the peripheral blood [38,39].
Although the complete list of client proteins for mitochon-
drial Hsp60 is not fully known, several studies demonstrated
that Hsp60 can interact with other proteins also in the extra-
mitochondrial environment. Table 8 shows a list of proteins
involved in several cellular pathways with which Hsp60 is
able to interact directly.
In mitochondria, Hsp60 works as a folding machine, inter-
acting with ATP, Hsp10 and mtHsp70 [40,41]. Aberrant
folding, for example, misfolding, is involved in a number of
severe conditions such as Parkinson’s and Alzheimer’s dis-
eases, familiar amyloidotic polyneuropathy and bovine spon-
giform encephalopathy, as well as its human counterpart,
Jakob--Creutzfeldt Disease [42,43]. In addition, atypical mito-
chondrial diseases with multisystem failure have been linked
to a deficiency in Hsp60 [44].
The substrates of the Hsp60/Hsp10 system are poorly
defined, but the combination of deficiency of mitochondrial
enzymes and proteins that are highly dependent on this
chaperoning system for folding is the likely trigger for many
diseases [44,45]. For instance, Hsp60 is important for the cor-
rect folding and assembling of dihydrofolate reductase [46]
and carbonicanhydrase II (HCAII) [47]. HCAII is the key
enzyme for acid--base balance, respiration, carbon dioxide
and ion transport, and also bone resorption, ureagenesis, glu-
coneogenesis, lipogenesis and body fluid generation in various
tissues [48]. Hsp60 specifically associates with mitochondrial
ATP synthase, the enzyme necessary to produce and hydrolyze
ATP [49]. It was demonstrated that this interaction occurs also
on the endothelial cell (EC) surface and, as a consequence
from the therapeutic point of view, it is important to protect
ATP synthase from degradation on EC membranes. Cell sur-
face ATP synthase acts to bind several ligands and to control
EC proliferation and differentiation. Its alteration causes
damages to EC homeostasis and plays a role in vasculitis path-
ogenesis [49]. Hsp60 interacts also with many factors involved
in apoptotic pathways and cell cycle regulation [37]. The
actions of Hsp60 could lead to the modification of those pro-
teins, and in this manner it could have a role in many diseases,
including carcinogenesis.
Table 6. Examples of chronic inflammatory conditions in which Hsp60 has been implicated as a stimulator of
inflammation.
Organ Disease Ref.
Heart Heart failure; Coronary vascular disease [137-140]
Kidney Glomerulonephritis [141]
Large bowel Inflammatory bowel diseases [19,142,143]
Lung Chonic obstructive pulmonary disease [20]
Oral cavity Periodontitis [144,145]
Pancreas Type 1 diabetes [146-151]
Skin Scleroderma, pemphigoid; Psoriasis; Dermatomyositis [152,153]
Synovial joints Rheumatoid arthritis; Juvenile idiopathic arthritis [154-157]
Vessels Vasculitis; Atherosclerosis [158-167]
Adapted from [2].
Figure 4. Highly conserved sequence segments in human
Hsp60 that have very similar counterparts in many other
Hsp60 and GroEL molecules from a variety of eukaryotic and
bacterial species. Shown are five highly conserved sequence
segments: 191 -- 203 in red, 246 -- 253 in green, 275 -- 286 in
blue, 363 -- 382 in yellow, and 402 -- 416 in magenta. These
molecular segments are potentially immunogenic and anti-
genic epitopes and, because of their similarity in many
species, could be cross-reactive sites for anti-Hsp60 anti-
bodies and drugs.
F. Cappello et al.
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Hsp60 seems to contribute to tumor cell survival, but this is
controversial. For example, it is known that Hsp60 interacts
with procaspase-3 both in mitochondria and cytosol [29-32].
In diverse cancer cells, it was demonstrated that Hsp60 in
combination with Hsp10 accelerates maturation of caspase-3
with concomitant mitochondrial activation of caspase-3 and
release of cytochrome c and Hsp60, participating in caspase-
3 activation by acting as a chaperone to promote maintenance
of procaspase-3 in a protease-sensitive state [29,30].
By contrast, other studies showed that Hsp60 may have an
antiapoptotic function through the binding of Hsp60 with
caspase-3 without activation of the latter [31,32]. In addition,
in cardiac myocytes, Hsp60 has antiapoptotic roles by form-
ing a macromolecular complex with Bax and Bak and,
thereby, blocking their ability to induce apoptosis [50].
Since Hsp60 is abundantly expressed in many human
tumors [51], Hsp60 may be considered a cancer-specific gene
product, a biomarker, involved in protection from apoptosis
of transformed cells. Hsp60 binds survivin, stabilizing its lev-
els, and curbing p53 function [52]. Elimination of
Hsp60 results in loss of the mitochondrial pool of survivin,
p53 increase and activation of p53-dependent apoptosis in
tumor cells [52].
In addition, Hsp60 has a role in metastasization [53]. It was
demonstrated in a patient with metastatic head and neck squa-
mous cell carcinoma that the role of Hsp60 in metastasization
occurs through activation of b-catenin, which has also been
implicated in promoting metastasis in various other types of
tumors [54]. Co-expression patterns of Hsp60 and b-catenin
in this model support a mechanism of b-catenin activation
by Hsp60 overexpression [53]. Hsp60 can also be found
on the surface of normal and tumor cells, and it appears
to be involved in the immune system activation and tumori-
genesis [38]. Surface Hsp60 has been found associated with
a3b1-integrin, a protein involved in the adhesion of meta-
static breast cancer cells [55]. Several aspects of tumor progres-
sion and development, including proliferation, modulation of
differentiation, invasion of surrounding tissues and metastasis
have been shown to be dependent on a3b1-integrin activity.
Induction of a3b1-integrin activity results in enhanced motil-
ity and adhesion of breast cancer cells. In addition,
a3b1 integrin stimulates endothelial cell proliferation and
angiogenesis. Therefore, therapeutic means that selectively
inhibit a3b1-integrin activation or ligand binding, by target-
ing integrin or its associated Hsp60, may inhibit tumor pro-
gression by disrupting the function of a3b1-integrin in
tumor cells and tumor vasculature [55].
The surface-exposed Hsp60 is also an agonist of the micro-
glial TREM 2 receptor. TREM 2 is a receptor expressed by
osteoclasts, and by myeloid and microglial cells, it has a pro-
tective role in bones and brain. Mutation of TREM 2 deter-
mines genetic disorders affecting bones and brain.
Hsp60 present onto the surface of astrocytes and neuroblas-
toma cells interacts with TREM2 in pathological conditions,
activating phagocytosis by microglial cells, while in normal
Figure 5. Amino acids involved in substrate binding in Hsp60.
Shown are hydrophobic/aromatic positions possibly involved
in substrate binding: Y199 red, Y203 blue, F204 magenta,
L234 cyan, L237 orange-brown, L259 yellow, V263 pink and
V264 green. Substrate (client polypeptide in need of
assistance for folding) binding is a key step in the chaperon-
ing process by Hsp60 and any alteration (or blocking) of the
structures involved is likely to impair protein folding.
Figure 6. Cysteine residues are present in human Hsp60 but
not in GroEL. The residues C237 (orange-brown), C442 (red),
and C447 (lemon-green) are shown. These residues have no
counterpart in GroEL and constitute convenient nucleophilic
binding sites for electrophilic drugs (see Section
Hsp60 inhibitors: new drugs for old diseases).
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conditions the TREM 2/Hsp60 complex has a role in coordi-
nating the functions of the various brain cell types [56].
Hsp60 also occurs in the extracellular space and in circula-
tion exported outside the cells via microvesicles such as exo-
somes [28]. It is assumed that circulating Hsps can have
immunostimulating as well as immunosuppressing effects,
depending on the circumstances in which the Hsps interact
with other cells. Extracellular Hsp60 can interact with a vari-
ety of receptors present on the plasma cell surface, such as
CD14, CD40, CD91 and TLRs [57,58]. Moreover, it was dem-
onstrated that Hsp60 is an inductor of inflammatory adipo-
cyte activity. Hsp60 binds an adipocyte receptor and,
thereby, Hsp60 influences the proinflammatory capacity of
adipocytes, thus contributing to obesity-associated inflamma-
tory disease leading to diabetes [59,60].
Lectin-like oxidized low-density lipoprotein receptor-1
(LOX-1) has previously been identified as a novel receptor
for Hsp60, and we hypothesize that LOX-1 through binding
to extracellular Hsp60 promotes microglia-mediated neuroin-
flammation. LOX-1 is essential in microglia for promoting an
inflammatory response in the presence of soluble neuronal-
injury signals such as extracellular Hsp60, thereby linking
neuroinflammation and neurotoxicity [61].
In conclusion, knowledge about these interactions is essen-
tial to developing new treatments for Hsp60 chaperonopa-
thies. The Hsp60 interactions in many cases can promote
disease. In this case, treatment ought to consider inhibition
blocking of the Hsp60 interactions (negative chaperonother-
apy). In the other cases, when the interaction of Hsp60 with
another molecule is antidisease, treatment ought to stimulate,
namely facilitate that interaction (positive chaperonotherapy).
The list of molecules that interact directly withHsp60 (Table 8)
is very important because it indicates possible targets for ther-
apeutics focusing on Hsp60, either to block the interaction or
to favor it.
7. Hsp60 structural features key for function
and potential targets for therapeutics
In this section, we provide images, cartoons, of the
Hsp60 molecule that represent approximations of what
the real molecule might look like. We emphasize features
of the Hsp60 molecule that can help to a) understand
structure--function relationships, including the assembling
of a functional chaperoning machine; b) infer the conse-
quences that amino acid changes (mutation or post-
translational modification) might have on these structure--
function relationships; c) visualize possible focal targets
for the binding of chemical compounds with predictable
high probability of profound functional effects -- this would
be useful in therapeutics; d) likewise, identify sites on to
which one could ligate reactive compounds that can help
in following Hsp60 as a biomarker -- this would be useful
in diagnosis and disease monitoring as well as in research;
and e) understand why anti-Hsp60 antibodies from any
given organism can cross-react with the Hsp60 from
many others.
We hope that these simple images will help nonstructural
biologists, physicians and pathologists, in figuring out what
portions of the molecule, that is, one or a few amino acids,
build sensitive spots amenable to binding by antibodies and/
or by specifically designed chemicals that will produce a
desired effect, such as inhibition of a given function in a path-
ogenically active Hsp60, or the functional boosting of a defec-
tive chaperonin. For a more accurate description of the
chaperonin GroEL and the ATP-driven mechanism of protein
folding (see below), the reader may consult [62-64].
Hsp60 (also called Cpn60) and its co-chaperone Hsp10
(Cpn10) represent the protein folding apparatus of mitochon-
dria, and the process in which they participate has been studied
using the bacterial homologues GroEL and GroES, respec-
tively [65]. The original experiments performed on Escherichia
coli led to the characterization of GroEL and GroES and, by
extension, facilitated the understanding of the structure and
function of the eukaryotic homologs Hsp60 (Cpn60) and
Hsp10 (Cpn10) [66]. Human Hsp60 in the mitochondria, sim-
ilarly to bacterial GroEL, forms a ring-shaped homo-oligomer
of seven subunits, and two rings associate to form a tetrade-
camer shaped like a barrel with a central cavity, which can
accommodate polypeptide substrates of up to 50 kDa or so.
The preferred substrates of Hsp60/Hsp10 complex are
unfolded proteins, whose folding is catalyzed in an ATP-
dependent manner. Shortly after GroEL binds one ATP mol-
ecule, the client polypeptide to be folded interacts with the
inner side of the central cavity by means of hydrophobic resi-
dues and ATP hydrolysis induces conformational changes
ATP
Mg2+
K+
Figure 7. ATP and Mg+/K+ binding sites on Hsp60. Shown are
two highly conserved sequences: 52-DGVTVAKEI-60 (orange-
brown), and 85-AGDGTTTATVL-95 (magenta) corresponding,
to the binding sites for Mg+/K+ (green and yellow spheres,
respectively) and ATP/ADP (red).
F. Cappello et al.
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(from cis to trans conformation). After these changes, GroES
and GroEL separate and the folded protein is released. GroES,
and presumably also Hsp10 in the mitochondria, act as a cap
covering the central cavity of the tetradecamer, opening and
closing the structure coordinating the behavior of the
Hsp60 monomers and regulating ATP hydrolysis [65,67,68].
In Figure 2, it is shown that each Hsp60 monomer is
constituted of three structural domains named apical, inter-
mediate and equatorial; it is important to realize that these
domains are distinct from the functional domains or modules
schematized in Figure 1, but they contain them.
On the basis of data from the GroEL crystal structure and
from the alignment of many diverse Hsp60 sequences from
different species, including humans, various authors, including
us, have identified highly conserved sequence segments and
residues, some of which are shown in Figure 4. The apical
domain includes two conserved sequences: 246-PLLII-
AED-253 (green), which contains five aliphatic residues,
and 275-AVKAPGFGDRRK-286 (blue) that is enriched in
charged residues. The conserved sequence 191-EGMQFDR-
GYISPY-203 (red) traverses the transition region from the
intermediate to the apical domain and includes several aro-
matic residues for substrate binding sites. Another two con-
served segments are 363-EKLQERLAKLAGGVAVIKVG-
382 (yellow), which connects the intermediate with the apical
domain; and 402-ATRAAVEEGIVPGGG-416 (magenta),
which connects the intermediate with the equatorial domain.
The charged residues at positions 275 -- 286 (blue) and 363
-- 382 (yellow) are exposed to the central cavity in the cis con-
formation while the glycine triplet at positions 402 -- 416
(magenta) binds ATP/ADP [69,70]. These similarities among
Hsp60 molecules from a variety of species are at the basis of
the immunological cross-reactions observed in many diseases
in which Hsp60 plays a role (see Section 3: Hsp60 and autoim-
mune diseases).
Hydrophobic/aromatic residues that contribute to substrate
binding are also highly conserved and are located in the apical
domain. These positions are: Y199, Y203, F204, L234, L237,
L259, V263 and V264 (Figure 5) [71,72]. Since substrate bind-
ing is in fact a sine qua non condition for folding, any alteration
(mutation, post-translational modification, modification or
blocking with chemical compounds) of the Hsp60 residues
involved in this process may result in a serious functional
defect (see Figure 1C), leading to protein misfolding and aggre-
gation. Defects in substrate binding as well as any of the other
Hsp60 defects outlined in Figure 1 may lead to disease (e.g.,
protein misfolding conditions). On the contrary, the
substrate-binding structures or any of the other critical func-
tional modules in Hsp60 offer an opportunity for therapeutics
if the chaperonin is actively involved in pathogenesis. In
the latter case, inhibition-blocking of Hsp60 (negative chaper-
onotherapy) may be a way to stop or delay disease progression
(see, for example, Section 8: Hsp60 inhibitors: new drugs for
old diseases).
The human Hsp60, but not GroEL, has cysteine residues
(Cys237, Cys442 and Cys447), shown in Figure 6, that are
of interest for developing Hsp60-binding compounds (see
discussion later).
The equatorial domain contains the residues at positions
52 -- 60 and 85 -- 95 implicated in the binding of ATP/
ADP and Mg2+/K+ ions (Figure 7) [7,72]. These sites are essen-
tial for the functioning of Hsp60. Therefore, any alteration of
these sites (mutation [see, e.g., Figure 3], post-translational
modification) or blocking them with a chemical compound
will most likely inactivate Hsp60. See also Figure 1A and B.
The apical domain contains the contact positions for
GroES binding represented by the hydrophobic residues
L234 and L237, and by N265 (Figure 8, blue). These residues
contact GroES at the conserved hydrophobic residues I25,
I26, L27 and A31 (cyan). The interaction between GroEL
and GroES is necessary for the typical chaperoning process
Figure 8. Amino acids involved in the interaction between
GroEL and its co-chaperone GroES. The cartoon represents a
three-dimensional model of the GroEL/GroES complex from
Escherichia coli showing two monomers (yellow on the left,
and red on the right) of the top ring of GroEL, and GroES
(orange-brown) on the top. Framed and highlighted are
residues that are thought to be crucial for the interaction
between GroEL and GroES as follows: the hydrophobic
conserved residues L234 and L237, and N265 on the surface
of GroEL are shown in blue, while the hydrophobic residues
I25, I26, L27, and A31 on the surface of GroES are shown
in cyan.
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during polypeptide folding and depends on the correct match
of amino acids in the interphase between the two molecules. It
follows that disruption of this interaction by modifying (e.g.,
mutation) or blocking (e.g., by using a chemical compound)
one or more of these essential residues will most likely cripple
Hsp60, impairing its chaperoning ability. See also Figure 1D.
Contacts between equatorial domains of contiguous mono-
mers are unchanged both in cis and in trans conformations
because the major rearrangements in the structure involve
mostly the apical and the intermediate domains. The interac-
tion is established by the conserved hydrophobic residues I6,
L73, L513, T517 and V521, which interact with the con-
served hydrophobic residues V39, L40, I49 and I60 on the
opposite surface (Figure 9). The interaction is completed by
opposite charge interactions between K4-E518 and
E61-R36. Tight assembly of rings is necessary for the correct
formation and functioning of the GroEL tetradecamer. Con-
sequently, disruption of intermonomer intraring interaction
(by alterations or blocking of the residues involved) will
most probably result in a functional defective Hsp60. See
also Figure 1F, which pertains to the formation of homo-
oligomers such as those of Hsp60.
Intermonomer contacts of the apical domain and interme-
diate domains are essential for allosteric switch between cis
(open cavity to receive the substrate molecule) and trans con-
formations. In the cis conformation Y203, V263 and
V264 interact from one face with D304, the unaligned posi-
tion 305, and G306 (Figure 10). In the trans conformation,
only two contacts at the apical domain interface are highly
conserved. These contacts involve E257 on one surface
and R268 and G269 on the opposite surface. The intermedi-
ate domain interacts with the contiguous apical domain in
the trans conformation and with the contiguous equatorial
domain in the cis conformation. Conserved residues at
positions 181 -- 183 of contiguous intermediate domains are
in contact only in trans, while within the peptide
383 -- 389 the same residues contact different regions of
the neighboring monomer in the cis and in the trans confor-
mation (Figure 10, black) [7]. As mentioned earlier (Figure 9),
tight assembly of rings is necessary for the correct formation
and functioning of the GroEL tetradecamer. Consequently,
disruption of intermonomer--intraring interaction (by altera-
tions or blocking of the residues involved) will most probably
result in a functional defective Hsp60. See also Figure 1F,
which pertains to the formation of homo-oligomers such as
those of Hsp60.
Interactions between rings occur via conserved hydropho-
bic residue V464, moderately conserved charged residues
K105, E461 and E467, and the small residues A108,
A109 and S463 (Figure 11). The opposite charged residues
are E434 and D345. These residues contribute to the salt-
bridge K105-E434 and to allosteric switch [7,73,74]. As correct
intraring interaction and allosteric changes are essential for
building a fully functional Hsp60 chaperoning machine, so
is the interaction between the two rings of the tetradecamer.
Several residues are crucial for the correct assembling of the
two-ringed machine and, therefore, alterations of these resi-
dues (mutation, post-translational modification, modification
or blocking with chemical compounds) can result in a failure
of tetradecamer formation. See also Figure 1E, pertaining to
allosteric changes, and Figure 1F, pertaining to the formation
of homo-oligomers such as those of Hsp60.
8. Hsp60 inhibitors: new drugs for old
diseases
In order to develop inhibitors of human Hsp60, it is crucial to
focus on structural differences between the widely studied
prokaryotic Hsp60 (GroEL) and its corresponding eukaryotic
Hsp60 (Cpn) [75,76]. For example, in contrast to GroEL the
eukaryotic Hsp60 possesses three cysteine residues (Cys237,
Cys442 and Cys447; Figure 6), which represent ideal nucleo-
philic binding sites for electrophilic drugs.
Figure 9. Intermonomer--intraring interaction in GroEL. The
cartoon represents a three-dimensional model of GroEL
from E. coli, showing only two monomers in one ring for the
sake of clarity, in the GroEL tetradecamer, one in yellow
(monomer to the right) and one in orange-brown (monomer
to the left). The contact residues (framed) are at the
equatorial domain interface between the two monomers.
Hydrophobic residues I6, L73, L513, T517and V521 (all in red)
interact with hydrophobic residues V39, L40, I49 and I60 (all
in light violet) on the opposite surface. The charged residues
K4-E518 and E61-R36 (all in blue) also participate in the
intermonomer--intraring interactions.
F. Cappello et al.
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Only two strategies have been applied up to now to develop
Hsp60 inhibitors. The first one aims at inhibiting ATP bind-
ing and hydrolysis, thus, affecting those ATP-dependent con-
formational changes crucial for the protein folding
function [77-79] (see Figure 1A and B, and Figure 7). The second
strategy aims at targeting the Hsp60s cysteine residues
(see Figure 6) either as oxidizable sites [80] or for covalent bind-
ing of the desired compound [81-83].
Ideally, when testing a novel compound targeting Hsp60,
its binding capability and docking site should be assessed
together with its efficacy in inhibiting ATP binding and
hydrolysis, and protein folding activity. Unfortunately,
these issues are rarely addressed comprehensively [79,81],
thus past studies leave several unanswered questions con-
cerning currently available Hsp60 inhibitors. This lack of
experimental information can be partially remedied by
resorting to biomolecular computational studies which, for
instance, have been conducted in silico to model the ATP-
binding pocket of Hsp60 in humans, E. coli and Brugia
malayi [84].
Several compounds, including 1,25-dihydroxyvitamin
d3 [85], bifenthrin [86], bortezomib [87], metformin [88] and
morphine [89] have been correlated with an overexpression
of Hsp60, as well as of other heat-shock proteins, generating
in some cases an antitumor effect. Treatment with the drug
bortezomib led to upregulation of the cell-surface expression
of Hsp60 thus triggering an immune response resulting in
phagocytosis of the tumor cell by dendritic cells [87]. Popular
drugs, such as mefipristone (RU486), have been correlated
with diminished levels of expression of the bacterial gene
for Hsp60, leading to the beneficial inhibition of Chlamydo-
phila pneumoniae infections [90]. Similarly, circulating levels
of Hsp60 were reduced in HIV patients after receiving com-
bination antiretroviral therapies (cART) [91]. Besides these
correlations of a given compound with the expressed levels
of Hsp60 without demonstrating a direct interaction, only
a few studies have been devoted to chaperonin-targeting
drugs.
Among ATPase activity targeting compounds, mizoribine -- an
imidazole-based immunosuppressant (Figure 12), can form a
complex with Hsp60 and, thus, affect the protein-folding activity
of the chaperonin [77,78]. A recent study showed that mizoribine
slowed down the folding cycle by affecting the ATP hydrolysis
cycle. Additionally, inhibition of the dissociation of the co-
chaperonin Hsp10 from the Hsp60/Hsp10 complex was sug-
gested to have a key role in the mizoribine activity. Interestingly,
the inhibitory functions were found different when studying
Hsp60/Hsp10 or GroEL/GroES systems, with the latter being
not significantly affected by mizoribine [79].
After the discovery of the interaction of mizoribine with
Hsp60, another heterocyclic compound, EC3016 (Figure 12),
was reported to block ATP binding and hydrolysis thus affecting
the protein-folding function of Hsp60 [78]. However, no updates
about the potential pharmacological use of this pyrazolo-
pirimidine derivative have appeared since the first report.
In addition to the above ATPase activity-targeting drugs,
other compounds (Figure 13) have been reported to directly
interact with cysteine residues of Hsp60 (Figure 6). For
instance, avrainvillamide and its dimer, whose inhibiting
activity of Hsp60 functions have not been yet demonstrated,
can alkylate the Hsp60 cysteine residues through the electro-
philic 3-alkylidene-3H-indole 1-oxide in moiety [83]. Epolac-
taene, which covalently binds to Cys442, was discovered to
inhibit the chaperoning activity of human Hsp60 [82]. While
the epoxide moiety is the most likely binding site to covalently
trap the thiolic ends of cysteine residues, an analysis of struc-
ture--activity relationship on epolactaene derivatives showed
that both the cyclic amide (lactam) and the ab-unsaturated
ketone are crucial moieties for inhibiting the chaperone activ-
ity [81]. Recently, also the tertiary butyl ester epolactaene
derivative, ETB, was shown to target mitochondrial transcrip-
tion in fission yeast [92].
Figure 10. Intraring interactions in the GroEL tetradecamer.
The cartoon represents a three-dimensional model of GroEL
from E. coli, showing only four monomers for the sake of
clarity, of the two rings (orange-brown and yellow, top ring;
and red and light violet, bottom ring), in the tetradecamer.
Large frame: intermonomer--intraring contacts of Y203,
V263 and V264 in the apical domain (forest-green color on
orange-brown monomer) interact with D304, the unaligned
position 305, and with G306 (forest-green color on yellow
monomer). E257 (cyan on yellow monomer) on one surface
interacts with R268 and G269 (cyan on orange-brown
monomer) on the opposite surface. Small frame: conserved
residues at positions 181 -- 183 and 383 -- 389 of the
contiguous intermediate domains are shown in black.
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Besides acting as nucleophilic counterpart for the electro-
philic epolactaene or its related derivative ETB, cysteine res-
idues of Hsp60 have been targeted also for sulfation by
suvanine, a sesquiterpene natural product of marine origin,
which was screened for interaction with Hsp60 through
chemical proteomics [93]. Additionally, given the typical
thiol/disulfide redox reaction of its cysteine residues,
Hsp60 was found to interact also with gossypol, a polyphe-
nolic drug that induces apoptosis through oxidative stress
[80].
Also other electrophilic compounds have been proven to
target Hsp60, although not in a specific or protein-selective
fashion. For instance, proteomic analysis revealed that
4-hydroxynonenal (HNE; Figure 14), an electrophilic a,b-
unsaturated aldehyde, targets Hsp60, together with several
other proteins involved in stress signaling, in a dose-
dependent increase in labeled proteins with increased
sequence coverage at higher concentrations [94]. Also in this
case, the binding site was not elucidated, although, by consid-
ering the electrophilic nature of the aldehyde, involvement of
Hsp60 cysteine residues cannot be excluded.
Recently, carboranylphenoxyacetanilide, a hypoxia-inducible
factor 1 alpha (HIF-1a) inhibitor, was proven to bind
Hsp60 as a primary target, although the exact binding site
was not identified [95]. Interestingly, a derivative of
carboranylphenoxyacetanilide (R1 = CH2CH3, R
2 = B(OH)2,
R3 = OH; Figure 15) showed a chaperone inhibition activity
two times higher than that of ETB [96,97].
As a perspective, besides targeting the chaperonin’s ATP-
binding site or cysteine residues, other regions of Hsp60 can
be surveyed to develop novel inhibitors. For instance, by tak-
ing advantage of recent knowledge gained about the mecha-
nism of refolding denaturated proteins [41], one can envisage
to target the site of interaction between the mithocondrial
chaperonin and its co-chaperonin (see Figure 8). Alternatively,
compounds can be developed to target the ability of Hsp60 to
form complexes with proteins involved in the apoptotic cas-
cade (see Table 8). For example, metal complexes of pyridyl-
substituted 1,2,4-oxadiazole [98,99], a five-membered heterocy-
cle often present in organic materials [100,101] and biologically
active compounds [102-104] have recently shown their potential
antitumor activity against human hepatoblastoma HepG2 and
colorectal carcinoma HT29 cells, [98], and their effect on
Hsp60 and Hsp60/pC3 complex formation is currently under
investigation by our group.
9. Conclusions
Hsp60 plays diverse roles in various cellular and extracellular
locations; some are physiological, normal roles but others are
not. In these latter instances, Hsp60 is an etiologic--pathogenic
factor and should be eliminated or blocked. The various roles
of Hsp60 depend on intrinsic functions of the molecule, which
in turn depend on the integrity of specific structures within the
entire molecule. In addition, some Hsp60 functions are linked
to the correct assembly of multimolecular machines, including
Hsp60 monomers and also other molecules. Thus, disruption
or blocking of certain spots in the monomer will have an
impact on its functions, including oligomerization and inter-
action with other molecules (networking), and thus interfere
with one or more of the roles played by the chaperonin inside
and outside the cell. This dependency of intrinsic and overall
functions on the integrity of specific structural sites opens
the road to developing compounds that will bind those sites
and, thereby, block Hsp60 when it is a pathogenic factor.
These compounds may have therapeutic potential if devoid
of unwanted side effects and if amenable to be delivered into
sick cells with an Hsp60 chaperonopathy.
10. Expert opinion
Hsp60 is a type I chaperonin present in virtually all species and
cells across the phylogenetic Domains Bacteria and Eukarya,
but it occurs only in a small minority of the members of the
third Domain, Archaea. In humans, the canonical residence
is the mitochondrion, but it can also reside and work outside
this organelle, in the cytosol, cell membranes, extracellular
space, biological fluids (plasma, cerebrospinal fluid) and secre-
tions (saliva, urine). The canonical function of Hsp60 in the
human mitochondrion (also named Cpn60) is assisting newly
Figure 11. Interring interactions in the GroEL tetradecamer.
For the sake of clarity, only four monomers are shown of the
E. coli GroEL two rings (orange-brown and yellow, top ring;
and red and light violet, bottom ring). Frame: the interac-
tions between rings involve a) V464, and the charged
residues K105, E461 and E467 (all in magenta on yellow
monomer); and b) the small residues A108, A109, and
S463 (cyan on yellow monomer). On the red monomer are
shown E434 and D345 (both blue), which contribute to the
salt-bridge K105-E434 and to allosteric switch.
F. Cappello et al.
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synthesized polypeptides in folding correctly. For this
chaperoning function, Hsp60 assembles into an oligomer
with a well-defined quaternary structure which, in turn, inter-
acts with an oligomer of the co-chaperonin Hsp10 (Cpn10).
The whole process requires ATP hydrolysis. While this is the
classical view of Hsp60 and its properties and function, now
we know that it plays other roles unrelated to protein folding
in a variety of locations beyond mitochondria. We also know
that Hsp60 is implicated in the pathogenesis of diverse patho-
logical conditions. As such, the chaperonin has become the
subject of studies aiming at determining its precise role as
etiologic-pathogenic factor and also aiming at inventing new
diagnostic and therapeutic ways centered on it.
Table 7. Examples of human tumors in which human Hsp60 levels have been found changed in relation to disease
status (i.e., tumor grading or staging).
Tissue/organ Tumors Ref.
Adrenal gland Adrenal Cushing’s tumor [168]
Bladder Transitional cell carcinoma; carcinosarcoma [169-171]
Bone marrow, blood, lymph nodes Acute myeloid leukemia; Hodgkin’s lymphoma [155,172-174]
Brain Astroglyoma; glioblastoma; meningioma [175-179]
Breast Breast ductal carcinoma [180,181]
Esophagus Oesophageal carcinoma [182,183]
Large bowel Adenocarcinoma [23,169,184-187]
Liver Hepatocellular carcinoma [188]
Lung Bronchial carcinoma [25,26,189,190]
Ovary Serous ovarian cancer [191]
Prostate Prostate carcinoma [24,192-194]
Stomach Gastric maltoma [195]
Uterus Exocervical carcinoma [22,196]
Adapted from [2].
Table 8. Molecules found to interact directly with Hsp60.
Hsp60 localization Molecule interacting with Hsp60 Ref.
Mitochondria Aldehyde dehydrogenase 2 [37]
ATP [40]
ATP synthase [197]
Dihydrofolatereductase [37,46]
Hsp10 [37,41]
Human Carbonicanhydrase II [37,198,47]
mtHsp70 [37]
Pro-caspase3 [28-31,37]
Survivin [52]
Cytosol Bax/Bak [50]
Beta-catenin [53]
p53 [52]
Pro-caspase3 [28-31,37]
Plasma membrane Adipocyte receptors [59,60]
Alpha-3-Beta-1 integrin [55]
ATP synthase [197]
CD14 [57,58]
CD40 [57,58]
CD91 [57,199]
Endothelial ATP synthase [197]
Microglial lectin-like oxidized low-density lipoprotein receptor-1 [61]
Microglial TREM 2 receptor [56]
Toll-Like Receptors [57,58,200-202]
NH2
NH2O-
N+
O
NO
OH
HH
OH
HO
H
Mizoribine EC3016
a Pyrazolopyrimidine derivative
N
N
N
N
HN
O
Compounds affecting Hsp60 ATPase activity
Figure 12. Proven Hsp60 inhibitors affecting ATP binding
and hydrolysis. See also Figure 1.A and B.
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In short, Hsp60 is an appropriate, convenient and obliga-
tory target for therapeutics. First, it has a variety of functions
in diverse locations inside and outside the cells and, therefore
its malfunction can result in pathologic conditions affecting
almost any tissue or organ. Second, Hsp60 intrinsic functions
(e.g., formation of oligomeric rings and double-rings, ATP
binding and hydrolysis, substrate recognition, allosterism,
interaction with other chaperones forming functional
networks) depend on the integrity of defined sites in its mol-
ecule, many of which have been mapped. Third, it has been
implicated in a variety of disorders in which it most likely
plays a primary pathogenic role thus justifying efforts to
develop anti-Hsp60 blocking agents. Last, there is already a
considerable amount of information on almost all aspects of
its structure and function, and on its pathogenicity, which
encourages and facilitates research on compounds that bind
Hsp60 at predefined sites with predictable impact on the mol-
ecule and its functions.
On the contrary, it is also true that there are still many
aspects of the Hsp60 molecule and its interactors that are
incompletely understood. These obscure patches in the avail-
able knowledge are difficult to negotiate when planning
experiments and strategies to develop pertinent drugs. In
other words, while the information available is encouraging
and justifies efforts to study Hsp60 and to develop ways to
control its activity, for example, to promote it (positive chap-
eronotherapy) when deficient or to block it (negative chaper-
onotherapy) when pathogenic, many questions are still
unanswered and obstacles are obvious. For instance, more
information is needed to establish a) when (e.g., at what
age) and why autologous Hsp60 becomes a pathogenic auto-
antigen and participates in autoimmune pathology; b) when
(e.g., at what age or stage of disease development) and why
Hsp60 induces cytokine formation leading to chronic persis-
tent inflammation; and c), when (e.g., at what tumor stage)
and why it turns in favor of a tumor rather than protecting
the host (i.e., protect the patient’s cells and tissues from
tumorigenesis). Clarification of these points will take inten-
sive research over considerable periods of time. However, spe-
cific analysis of the Hsp60 molecular features and a search for
active compounds aimed at defined structural sites that might
affect its functioning should continue without interruption.
No doubt that some of these compounds will offer therapeu-
tic hopes. Further, it is likely that the compounds will be
O
H
OH
HNE
Figure 14. HNE (4-hydroxynonenal), an electrophilic com-
pound targeting proteins involved in stress signaling.
Carboranylphenoxyacetanilide derivatives
R1
= BH
O
O
N
H R3
R2
Figure 15. General structure of carboranylphenoxyacetani-
lide derivatives. The most active Hsp60 inhibitor found had
this structure: R1 = CH2CH3, R
2 = B(OH)2, R
3 = OH.
(+)-Avrainvillamide
N
H
N O
O N
O
O
H3C CH3
CH3
CH3
NHOO
O
OH
OO
Epolactaene
NHOO
O
OH
OO
ETB
Compounds targeting Hsp60 cysteine residues
Gossypol
OH O
OHO
HO
HO
OH
OH
O
OSO3H
Suvanine
Figure 13. Compounds interacting with Hsp60 cysteine residues through covalent binding (epolactaene, the tertiary butyl
ester epolactaene derivative ETB, and avrainvillamide), redox processes (gossypol) or sulfation (suvanine). See also Figure 6.
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useful tools for dissecting structure--function relationships at
the biochemical level, and also at the biological level, using
model systems in vivo (e.g., mouse) and in vitro (e.g., human
cell primary cultures, and cell lines). We can, then, say that
although more research is needed to elucidate basic aspects
of Hsp60 structure, function and biology, and to develop
delivery systems for active compounds that will target only
the pathological molecule in the sick cell, what is already
available allows us to predict that significant developments
will occur in the near future. These advances pertain to the
use of Hsp60 as a) biomarker for diagnosis and assessing prog-
nosis, and monitoring disease status and response to
treatment; and b) target for developing new drugs that will
modulate or block its activity.
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